Liminal BioSciences Inc.

LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP

Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder

Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management

Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP

Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?

Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price

Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript

Liminal BioSciences to Present at BIO CEO & Investor Conference

Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript

Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript

Liminal Biosciences to Present at Upcoming Investor Conferences

Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

Liminal BioSciences Announces Closing of Sale of Priority Review Voucher

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript